Real world usage of bevacizumab-bvzr biosimilar in US oncology practice
04 March 2022
- Bevacizumab is commonly used to treat solid tumors. However, little is known about the manner and the extent to which bevacizumab biosimilars are utilised in real world oncology practice in the United States
- A retrospective analysis of medical and pharmacy claims between January 24, 2019, and July 31, 2020, was performed
- The most common indications observed for bevacizumab-bvzr were metastatic colorectal cancer (mCRC; 51.0%), cancer of the female genital organs (CFGO; 27.2%), glioblastoma (11.2%), and non–small cell lung cancer (8.7%)
- Bevacizumab-bvzr was used in chemotherapy combination regimens for patients with mCRC and CFGO
Click here to learn more.
About SVMPharma
SVMPharma is an innovative strategic consultancy and CRO, with a focus in Real World Evidence (RWE) for pharmaceutical and biotechnology companies. SVMPharma delivers clinical trials within UK and Europe.
About DISTILL
DISTILL is a new EDC launched by SVMPharma. As a CRO discover the benefits of DISTILL as part of your service offering and take back control of your clinical trials. DISTILL allows you to develop and manage every aspect of your trials from start to finish. Move away from the restrictions and costs associated with legacy systems.
For more information, please visit www.svmpharma.com and contact us at enquiry@svmpharma.com
Ref: MAR2022BS001